BioGen Updates Its Spinoff Plans

BioGen (BIIB) has finally chosen a name for its upcoming hemophilia drug focused spinoff. The new company will be called Bioverativ and it will eventually trade on the Nasdaq under the ticker ‘BIVV’. Bioverativ will be a global biotech company ‘focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.’ It’s growing… Read More »